This product is a chimeric (mouse/human) monoclonal antibody with glycosylation site in Fc region. The SM03 with enhanced ADCC specifically binds human CD22 and can be potentially used in the treatment of lymphomas and other autoimmune diseases.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G077E | Anti-CD22 immunotoxin RFB4 (IgG)-PE | Cytotoxicity assay, Function study | |
AGTO-G077D | Anti-CD22 immunotoxin RFB4 (IgG)-DT | Cytotoxicity assay, Function study | |
AGTO-G077G | Anti-CD22 immunotoxin RFB4 (IgG)-Gel | Cytotoxicity assay, Function study | |
AGTO-G077R | Anti-CD22 immunotoxin RFB4 (IgG)-RTA | Cytotoxicity assay, Function study | |
AGTO-G077S | Anti-CD22 immunotoxin RFB4 (IgG)-Sap | Cytotoxicity assay, Function study |
There are currently no Customer reviews or questions for Gly-111LC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.